Nektar Therapeutics
NASDAQ Global SelectTotal Valuation
Nektar Therapeutics carries a market capitalization of 2.13B, placing it among publicly traded companies globally. Its enterprise value stands at 2.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.13B |
| Enterprise Value | 2.06B |
Share Statistics
Nektar Therapeutics currently has 29.47M shares outstanding.
| Shares Outstanding | 29.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 38.09 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -10.73 |
| P/OCF Ratio | -10.72 |
Enterprise Valuation
| EV / Sales | 46.28 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Nektar Therapeutics maintains a current ratio of 19.42, meaning it holds 19.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 217.92, indicating elevated leverage, while an interest coverage ratio of -3.72 demonstrates limited ability to service its debt obligations.
| Current Ratio | 19.42 |
| Quick Ratio | 18.63 |
| Debt / Equity | 217.92 |
| Debt / EBITDA | N/A |
| Interest Coverage | -3.72 |
Financial Efficiency
| Return on Equity (ROE) | -451.78 |
| Return on Assets (ROA) | -112.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 62,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Nektar Therapeutics's stock has gained approximately 84.6441% over the past 52 weeks. The 50-day moving average sits at 71.42, while the 200-day moving average is 64.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | 84.6441% |
| 50-Day Moving Average | 71.42 |
| 200-Day Moving Average | 64.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nektar Therapeutics generated 44.46M in revenue and converted that into -116.50M in net income, yielding earnings per share of -4.80. EBITDA reached -88.34M, while operating income came in at -88.88M.
| Revenue | 44.46M |
| Gross Profit | 33.60M |
| Operating Income | -88.88M |
| Pretax Income | -112.81M |
| Net Income | -116.50M |
| EBITDA | -88.34M |
| EBIT | -88.88M |
| Earnings Per Share (EPS) | -4.80 |
Cash Flow
Nektar Therapeutics produced -158.02M in operating cash flow over the past twelve months. After subtracting -150,000.00 in capital expenditures, free cash flow totaled -158.17M - equivalent to -6.52 per share.
| Operating Cash Flow | -158.02M |
| Capital Expenditures | -150,000.00 |
| Free Cash Flow | -158.17M |
| FCF Per Share | -6.52 |
Margins
Nektar Therapeutics operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -199.92 and net profit margin of -262.06 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -199.92 |
| Pretax Margin | -253.75 |
| Profit Margin | -262.06 |
| EBITDA Margin | -198.71 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -34.50 |
| FCF Yield | -9.32 |
Stock Splits
Nektar Therapeutics's most recent stock split took place on June 9, 2025 with a 15:1 split ratio.
| Last Split Date | 6/9/2025 |
| Split Ratio | 15:1 |
Scores
Nektar Therapeutics posts an Altman Z-Score of -30.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -30.93 |